These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 26473986)
1. Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis. Wang J; Devenport J; Low JM; Yu D; Hitraya E Arthritis Care Res (Hoboken); 2016 Jun; 68(6):882-5. PubMed ID: 26473986 [TBL] [Abstract][Full Text] [Related]
2. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604 [TBL] [Abstract][Full Text] [Related]
3. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318 [TBL] [Abstract][Full Text] [Related]
4. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471 [TBL] [Abstract][Full Text] [Related]
5. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Shafran IH; Alasti F; Smolen JS; Aletaha D Ann Rheum Dis; 2020 Jul; 79(7):874-882. PubMed ID: 32371387 [TBL] [Abstract][Full Text] [Related]
6. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab. Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637 [TBL] [Abstract][Full Text] [Related]
7. Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study. Drobinski PJ; Bay-Jensen AC; Karsdal MA; Sardar S; Siebuhr AS Arthritis Res Ther; 2021 Jan; 23(1):13. PubMed ID: 33413588 [TBL] [Abstract][Full Text] [Related]
8. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859 [TBL] [Abstract][Full Text] [Related]
9. Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis. Aizu M; Mizushima I; Nakazaki S; Nakashima A; Kato T; Murayama T; Kato S; Katsuki Y; Ogane K; Fujii H; Yamada K; Nomura H; Yachie A; Yamagishi M; Kawano M Mod Rheumatol; 2018 Jul; 28(4):592-598. PubMed ID: 28880691 [TBL] [Abstract][Full Text] [Related]
10. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Hirata S; Marotta A; Gui Y; Hanami K; Tanaka Y Arthritis Res Ther; 2015 Oct; 17():280. PubMed ID: 26449724 [TBL] [Abstract][Full Text] [Related]
11. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis. Kizaki K; Yamashita F; Hayashi T; Funakoshi N Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459 [TBL] [Abstract][Full Text] [Related]
12. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients. Lee SJ; Park W; Park SH; Shim SC; Baek HJ; Yoo DH; Kim HA; Lee SK; Leee YJ; Park YE; Cha HS; Park JK; Lee EY; Lee EB; Song YW J Immunol Res; 2015; 2015():487230. PubMed ID: 25922848 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI. Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733 [TBL] [Abstract][Full Text] [Related]
14. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study. Sagawa A Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804 [TBL] [Abstract][Full Text] [Related]
16. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis. Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586 [TBL] [Abstract][Full Text] [Related]
17. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial]. Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361 [TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Kaneshiro S; Ebina K; Hirao M; Tsuboi H; Nishikawa M; Nampei A; Nagayama Y; Takahi K; Noguchi T; Owaki H; Hashimoto J; Yoshikawa H Mod Rheumatol; 2017 Jan; 27(1):42-49. PubMed ID: 27181115 [TBL] [Abstract][Full Text] [Related]
19. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis. Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951 [TBL] [Abstract][Full Text] [Related]
20. Can tocilizumab decrease cartilage oligomeric matrix protein levels and disease activity in patients with long-standing rheumatoid arthritis? Benucci M; Meacci F; Manfredi M; Gobbi FL; Infantino M; Ricci C; Sarzi-Puttini P; Atzeni F Curr Rheumatol Rev; 2014; 10(2):131-5. PubMed ID: 25599685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]